Literature DB >> 31735300

Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?

Sarah R Verhoeff1, Michel M van den Heuvel2, Carla M L van Herpen1, Berber Piet2, Erik H J G Aarntzen3, Sandra Heskamp4.   

Abstract

Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Checkpoint inhibitors; Immunotherapy; Molecular imaging; PD-1; PD-L1; immunoPET

Mesh：

Substances：

Year:  2019        PMID： 31735300     DOI： 10.1016/j.cpet.2019.08.008

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  12 in total

Review 1.  Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.

Authors:  Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy
Journal:  Front Med (Lausanne)       Date:  2022-06-06

Review 2.  Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.

Authors:  Louis Lauwerys; Evelien Smits; Tim Van den Wyngaert; Filipe Elvas
Journal:  Biomedicines       Date:  2022-05-05

3.  Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies.

Authors:  Harm Westdorp; Sarah R Verhoeff; Martin Gotthardt; Carla M L van Herpen; Michel M van; den Heuvel; Sandra Heskamp; Erik H J G Aarntzen
Journal:  J Nucl Med       Date:  2022-01-20       Impact factor: 10.057

Review 4.  Insight into the Development of PET Radiopharmaceuticals for Oncology.

Authors:  Joseph Lau; Etienne Rousseau; Daniel Kwon; Kuo-Shyan Lin; François Bénard; Xiaoyuan Chen
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 5.  Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.

Authors:  Filippo Galli; Jesus Vera Aguilera; Belinda Palermo; Svetomir N Markovic; Paola Nisticò; Alberto Signore
Journal:  J Exp Clin Cancer Res       Date:  2020-05-18

6.  Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues.

Authors:  Marcus P Kelly; Sosina Makonnen; Carlos Hickey; T Cody Arnold; Jason T Giurleo; Richard Tavaré; Makenzie Danton; Christian Granados; Ishita Chatterjee; Drew Dudgeon; Marc W Retter; Dangshe Ma; William C Olson; Gavin Thurston; Jessica R Kirshner
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

7.  Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model.

Authors:  Jun Zhao; Xiaoxia Wen; Tingting Li; Sixiang Shi; Chiyi Xiong; Yaoqi Alan Wang; Chun Li
Journal:  ACS Omega       Date:  2020-04-08

Review 8.  FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma-An Updated Overview.

Authors:  Conrad-Amadeus Voltin; Jasmin Mettler; Jirka Grosse; Markus Dietlein; Christian Baues; Christine Schmitz; Peter Borchmann; Carsten Kobe; Dirk Hellwig
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

Review 9.  PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions.

Authors:  Marcus Unterrainer; Michael Ruzicka; Matthias P Fabritius; Lena M Mittlmeier; Michael Winkelmann; Johannes Rübenthaler; Matthias Brendel; Marion Subklewe; Michael von Bergwelt-Baildon; Jens Ricke; Wolfgang G Kunz; Clemens C Cyran
Journal:  Eur Radiol Exp       Date:  2020-11-17

Review 10.  PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions.

Authors:  Chukwuka Eze; Nina-Sophie Schmidt-Hegemann; Lino Morris Sawicki; Julian Kirchner; Olarn Roengvoraphoj; Lukas Käsmann; Lena M Mittlmeier; Wolfgang G Kunz; Amanda Tufman; Julien Dinkel; Jens Ricke; Claus Belka; Farkhad Manapov; Marcus Unterrainer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-24       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.